CClinicalTrials.gg
Active, not recruitingNCT05421780Updated Nov 9, 2023

Post-prandial Glycaemic Controlling Effects of BSG in Singapore Adults With Metabolic Syndrome

An interventional study of autoclaved BSG-containing biscuits and bio-transformed BSG-containing biscuits in Metabolic Syndrome, Diabetes and Diet Modification, sponsored by National University of Singapore. Active, not recruiting at 1 site in Singapore. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-11-09.

Sponsored by National University of Singapore · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
35 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to assess the glycaemic controlling effects of BSG and bio-transformed BSG-containing biscuits in Singapore adults with MetS. The investigators hypothesized that consumption of BSG and bio-transformed BSG containing biscuit will improve glycaemic control.

Read the detailed description

This is a double-blind, randomised, crossover experiment. During the 3-week, 19 subjects will participate in a 3 meal tolerance test (MTT). During each MTT session, all subjects are required to consume 90 g biscuits (either control, autoclaved BSG or bio-transformed BSG biscuits) and monitored over a period of 240 minutes. All three types of biscuits will be consumed at a randomised sequence during this 3-week period. Post-prandial blood glucose, insulin, lipid and amino acid responses, breath analysis, body composition, blood pressure, appetite assessment, and any other glycaemic biomarkers will be assessed.

02

Conditions studied

  • Metabolic Syndrome
  • Diabetes
  • Diet Modification

Keywords

  • Metabolic Syndrome
  • middle-aged and older adults
  • Post-prandial Glycaemic response
  • bio-transformed food
03

In context

Metabolic Syndrome

1,964 studies on the registry are indexed under Metabolic Syndrome; 330 are open to participants now.

This study's enrollment of 16 is below the median of 60 across 1,460 interventional studies indexed under Metabolic Syndrome.

Browse Metabolic Syndrome studies →

Lead sponsor

National University of Singapore is the lead sponsor of 206 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male and female participants, aged 35-85 years old
  • English-literate and able to give informed consent in English
  • Willing to follow the study procedures
  • Meet any 3 of the 5 following NCEP-ATP III MetS criteria: waist circumference > 102 cm (male), > 88 cm (female) (For Asian population: Waist circumference > 90 cm (male), > 80 cm (female)); fasting glucose concentration ≥ 100 mg/dL or on medication; triglyceride ≥ 150 mg/dL or on medication; high density lipoprotein cholesterol (HDL) \< 40 mg/dL (male), \< 50 mg/dL (female); systolic or diastolic blood pressure > 130/85 mmHg or on medication);

Exclusion criteria

Exclusion Criteria:

  • Significant change in weight (≥ 3 kg body weight) during the past 3 months
  • Allergy to barley, wheat, corn, egg, or other ingredients found inside the biscuits.
  • Acute illness at the study baseline
  • Exercising vigorously* over the past 3 months. *Defined as having > 6 metabolic equivalents of exercise daily; approximately 20 mins of moderate intensity exercise (e.g. slow jogging) a day
  • Following any restricted diet (e.g. vegetarian)
  • Smoking
  • Have a daily intake of more than 2 alcoholic drinks per day
  • Taking dietary supplements or food which may impact the outcome of interests (e.g. fermented foods, probiotic supplement etc.)
  • Consumption of antibiotics over past 3 months.
  • Pregnant, lactating, or planning pregnancy in the next 6 months
  • Insufficient venous access to allow the blood collection
  • Prescribed and taking antihypertensive/cholesterol-lowering/ type-2 diabetic medication which started less than 3 years prior to the intervention participation
  • High current intake of fibre* from brown rice or wholemeal products. *High, moderate or low intake taken as ≥ 6 servings, 4 - 5 servings, and ≤ 3 servings daily respectively based on My Healthy Plate guidelines
  • High current intake of fibre* from vegetables. * High, moderate or low intake taken as ≥ 2 servings, 2 servings, and ≤ 1 serving respectively based on My Healthy Plate guidelines
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Placebo comparator
    Control biscuits group

    For each MTT, subjects are to consume 90 g control biscuits as their breakfast within 15 mins.

    Dietary Supplement: control biscuits

  • Experimental
    autoclaved BSG-containing group

    For each MTT, subjects are to consume 90 g autoclaved BSG-containing biscuits as their breakfast within 15 mins.

    Dietary Supplement: autoclaved BSG-containing biscuits

  • Experimental
    bio-transformed BSG-containing group

    For each MTT, subjects are to consume 90 g bio-transformed BSG-containing biscuits as their breakfast within 15 mins.

    Dietary Supplement: bio-transformed BSG-containing biscuits

Interventions

  • Dietary supplementautoclaved BSG-containing biscuits

    Consumption of autoclaved BSG-containing biscuits as breakfast.

  • Dietary supplementbio-transformed BSG-containing biscuits

    Consumption of bio-transformed BSG-containing biscuits as breakfast.

  • Dietary supplementcontrol biscuits

    Consumption of plain biscuits as breakfast.

06

What researchers measure

Primary outcomes

  1. Change in blood glucose concentration

    Glucose concentration in the blood will be measured

    Time frame: Every week (week 1, week 2 and week 3)

  2. Change in blood insulin concentration

    Insulin concentration in the blood will be measured

    Time frame: Every week (week 1, week 2 and week 3)

  3. Change in blood triglyceride concentration

    Triglyceride concentration in the blood will be measured

    Time frame: Every week (week 1, week 2 and week 3)

  4. Change in blood cholesterol concentration

    Total cholesterol concentration in the blood will be measured

    Time frame: Every week (week 1, week 2 and week 3)

  5. Change in blood Low-density Lipoprotein-cholesterol (LDL) concentration

    Low-density Lipoprotein-cholesterol concentration in the blood will be measured

    Time frame: Every week (week 1, week 2 and week 3)

  6. Change in High-density Lipoprotein-cholesterol (HDL) concentration

    High-density Lipoprotein-cholesterol concentration in the blood will be measured

    Time frame: Every week (week 1, week 2 and week 3)

  7. Change in blood amino acid concentration

    Amino acid concentration in the blood will be measured

    Time frame: Every week (week 1, week 2 and week 3)

Secondary outcomes

  1. Change in appetite assessed by visual analogue scale

    Visual analogue scale will be used to assess appetite.

    Time frame: Every week (week 1, week 2 and week 3)

  2. Change in breath CH4 and H2 concentrations

    CH4 and H2 concentrations will be measured by breath analyzer

    Time frame: Every week (week 1, week 2 and week 3)

  3. Change in weight and height

    Weight (in kilograms) and height (in meters) will be combined to report BMI in kg/m\^2

    Time frame: Every week (week 1, week 2 and week 3)

  4. Change in waist circumference

    Waist circumference (in cm) will be measured

    Time frame: Every week (week 1, week 2 and week 3)

  5. Change in blood pressure

    Systolic and diastolic blood pressure (in mmHg) will be measured by a blood pressure monitor.

    Time frame: Every week (week 1, week 2 and week 3)

07

Study locations

1 site
  • Yujing Xu
    Singapore, 117543, Singapore
08

References and documents

Individual participant data

Plan to share: No — Electronic copies of the data with identifiable participant information will be kept on a secure website with access limited to Dr. Kim and Dr. Kim's research staff. All data will be de-identified prior to statistical analyses.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05421780
Lead sponsor
National University of Singapore
Collaborators
Ministry of Education, Singapore
Responsible party
Jung Eun Kim (Assistant Professor, National University of Singapore) — Principal investigator
First posted
Jun 16, 2022
Start date
Jun 29, 2022
Primary completion
Dec 13, 2022
Completion
Jul 2024 (estimated)
Last update
Nov 9, 2023

Study contacts

Jung Eun Kim
principal investigator · Food Science and technology, Faculty of Science, National University of Singapore

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion